Physician profile
Jeffrey Cronk
NPI 1811956220
$1,031.95
in general payments reported to CMS, 2019-2025
22 companies · $305 in 2025
The $305 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.65 · 2022: $143 · 2023: $239 · 2024: $277 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.59 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $172.05 | 2022-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $125.32 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $106.31 | 2022-2024 | Opdivo, Krazati, Augtyro |
| Coherus Oncology, INC. | $64.42 | 2023 | |
| Gilead Sciences, INC. | $54.21 | 2024-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $49.42 | 2024-2025 | Welireg, Keytruda Qlex, Keytruda |
| Taiho Oncology, INC. | $46.47 | 2022-2025 | |
| Daiichi Sankyo INC. | $45.57 | 2024 | Enhertu |
| Janssen Biotech, INC. | $42.00 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $41.20 | 2021-2023 | Imbruvica |
| Astrazeneca Pharmaceuticals LP | $38.95 | 2023 | Enhertu |
| Pfizer INC. | $33.07 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.01 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.17 | 2021 | |
| Tersera Therapeutics LLC | $21.52 | 2025 | Zoladex |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $20.74 | 2025 | Jakafi, Niktimvo |
| Amgen INC. | $20.70 | 2022 | |
| Lilly USA, LLC | $20.49 | 2021 | |
| Jazz Pharmaceuticals INC. | $20.22 | 2022 | |
| Eisai INC. | $20.21 | 2025 | |
| Adc Therapeutics America, INC. | $19.46 | 2025 | |
| Mirati Therapeutics, INC. | $14.44 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Cronk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.